Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:47:51.924Z.
Calculation as of: 2026-10-06T19:47:51.924Z.
Quote observation: 2026-10-06T19:41:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2239cca652f31aeacf416f33e6d20b1e6c1b9088f917a2c9fa2f7c7bfc29848
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2014-06-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$6.95M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.31M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.46M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.18M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.63M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.74M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.03M | N/A | 6.05 | 13.36 | 13.36 |
| KALA BIO, Inc. (KALA)vs › | $6.96M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.76M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2014-06-30 | 57091.04 |
| 2014-06-27 | 57192.34 |
| 2014-06-26 | 59911.60 |
| 2014-06-25 | 56386.81 |
| 2014-06-24 | 54271.70 |
| 2014-06-23 | 64140.61 |
| 2014-06-20 | 64240.69 |
| 2014-06-19 | 50345.37 |
| 2014-06-18 | 54171.62 |
| 2014-06-17 | 51553.66 |
| 2014-06-16 | 51553.66 |
| 2014-06-13 | 51553.66 |
| 2014-06-12 | 51553.66 |
| 2014-06-11 | 51553.66 |
| 2014-06-10 | 51352.28 |
| 2014-06-09 | 50345.37 |
| 2014-06-06 | 61421.35 |
| 2014-06-05 | 42894.25 |
| 2014-06-04 | 42894.25 |
| 2014-06-03 | 34033.47 |
| 2014-06-02 | 34033.47 |
| 2014-05-30 | 34033.47 |
| 2014-05-29 | 34033.47 |
| 2014-05-28 | 30609.98 |
| 2014-05-27 | 31315.43 |
| 2014-05-23 | 36952.89 |
| 2014-05-22 | 27890.72 |
| 2014-05-21 | 27890.72 |
| 2014-05-20 | 27890.72 |
| 2014-05-19 | 27890.72 |
| 2014-05-16 | 27890.72 |
| 2014-05-15 | 26783.74 |
| 2014-05-14 | 26883.82 |
| 2014-05-13 | 26883.82 |
| 2014-05-12 | 26883.82 |
| 2014-05-09 | 26582.35 |
| 2014-05-08 | 26582.35 |
| 2014-05-07 | 27992.02 |
| 2014-05-06 | 25978.21 |
| 2014-05-05 | 26783.74 |
